VYNE Therapeutics Inc. · NASDAQ:VYNE

VYNE Therapeutics — Investor Presentation (March 2025)

41 slides from VYNE Therapeutics's investor presentation, March 2025

  1. Slide 1: Corporate Presentation March 2025

    Corporate Presentation March 2025

  2. Slide 2: Forward Looking Statements and Important Notes

    Forward Looking Statements and Important Notes This presentation by VYNE Therapeutics Inc. (“VYNE”) includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements regarding VYNE’s development plans and timeline

  3. Slide 3: Investment Highlights

    Investment Highlights (NASDAQ: VYNE) Advancing novel BET inhibitor platform to improve the lives of patients suffering from immuno-inflammatory conditions Innovative • BET inhibition represents a novel target for the treatment of immune-mediated diseases: Addressing the complex signaling of I&I dise

  4. Slide 4: Building a Leading Early-Stage Pipeline to Address Unmet Needs in I&I Conditions

    Building a Leading Early-Stage Pipeline to Address Unmet Needs in I&I Conditions Route of Current Stage Program Indication(s) Status / Next Anticipated Rights Administration Preclinical Phase 1 Phase 2 Phase 3 Milestones InhiBETTM Platform - Library of NCE BET Inhibitors for Any Indication Worldwide

  5. Slide 5: InhiBET BET Inhibitor Platform

    InhiBET BET Inhibitor Platform Bromodomain & Extra-Terminal Domain (BET) Inhibition for Immunology and Inflammatory Diseases 5

  6. Slide 6: BET Proteins: Key Epigenetic Regulators of NF-kB

    BET Proteins: Key Epigenetic Regulators of NF-kB, a Master Orchestrator of Inflammation Cytokine receptor TCR TLR e.g., IL-17, TNF • BET proteins are epigenetic regulators of transcription driven by NF-kB. IKKγ Cytokine protein IKKα IKKβ • NF-kB is a critical transcription factor in inflammation IκB

  7. Slide 7: BET Inhibition: A Novel Mechanism for the Treatment of I&I Conditions

    BET Inhibition: A Novel Mechanism for the Treatment of I&I Conditions BET Inhibition’s Impact on Multiple Inflammatory Pathways Provides Potential to Address a Broad Range of Immune-Mediated Diseases Primary Cell nucleus Type1 Th1/Tc1 Th17 Myeloid cells B Cells NFκB BET-inhibition • TNF Cytokine RNA

  8. Slide 8: Clinical Development Strategy

    Clinical Development Strategy PoC studies in Vitiligo, PsO and RA serve as potential gateways to other large, strategically attractive markets unlocks potential for broad development strategy across range of immune-mediated diseases Proof-of- Strategic Concept Markets Vitiligo PsO RA Nonclinical, cl

  9. Slide 9: VYNE's Drug Design Strategy

    VYNE’s Drug Design Strategy Optimize benefit/risk profile of BET inhibitors to target immune-mediated diseases Repibresib (VYN201) VYN202 Pan-BD BET Inhibitor BD2-Selective BET Inhibitor Maximize local effect & Improve efficacy and tolerability minimize systemic exposure through BD2-selectivity • Ti

  10. Slide 10: Repibresib (VYN201): Vitiligo

    Repibresib (VYN201): Vitiligo

  11. Slide 11: Vitiligo Represents a Large and Growing Market Opportunity

    Vitiligo Represents a Large and Growing Market Opportunity Addressable Market : a Significant Unmet Need $ in millions • Market penetration: Opzelura is the U.S. vitiligo net sales 1.9M only product approved for treatment estimated ~$180M $725 of vitiligo ~2.5 years post-launch2 • Patient activation

  12. Slide 12: Repibresib (VYN201): Phase 1 Proof-of-Concept

    Repibresib (VYN201): Phase 1 Proof-of-Concept

  13. Slide 13: Repibresib (VYN201): Phase 1b Study in Active Vitiligo Patients

    Repibresib (VYN201): Phase 1b Study in Active Vitiligo Patients StudyStudy Design Design: Treatment on the face and target lesion on trunk of active vitiligo patients for up to 16 weeks of QD treatment • N = up to 30: 3 cohorts, evaluating 0.5%, 1.0% and 2.0% strengths • Safety assessments include T

  14. Slide 14: Promising Onset of Action and F-VASI Response

    Promising Onset of Action and F-VASI Response Repibresib (VYN201) Phase 1b: QD Treatment in 100% active disease study population 0% 90% Individual Subject F-VASI Response Week 16 -5% 80% -7.5% F-VASI75 -10% 70% Mean % CFB in F-VASI -15% 60% (p = 0.0138 vs. VYN201 0.5%)* -20% F-VASI50 50% % CFB in F-

  15. Slide 15: Demonstrated Competitive Results at 16 Weeks vs. JAK Class at 24 Weeks

    Demonstrated Competitive Results at 16 Weeks vs. JAK Class at 24 Weeks Repibresib (VYN201) Phase 1b: QD Treatment in 100% active disease study population 0.0% JAK Class (P2b) Week 24 data -5.0% -7.5% -10.0% Mean % CFB in F-VASI -15.0% Litfulo -18.5% -20.0% -25.0% -30.0% -30.2% Rinvoq Povorcitinib -3

  16. Slide 16: Key Takeaways from Repibresib (VYN201) Phase 1b Results

    Key Takeaways from Repibresib (VYN201) Phase 1b Results • Believed to be first clinical demonstration of BET inhibitor’s effect in I&I disease1 • Significant clinical response demonstrated with once-daily dosing • Rapid onset of action with clear evidence of dose response • Upregulation of WNT pathw

  17. Slide 17: Repibresib (VYN201) Phase 2b in Non-Segmental Vitiligo

    Repibresib (VYN201) Phase 2b in Non-Segmental Vitiligo (NSV) Top-line results from 24-week vehicle-controlled treatment period expected mid-2025 N = ~180 subjects with NSV (active and stable disease) PART 1: Vehicle-controlled treatment period PART 2: Extension treatment period Safety follow-up (24

  18. Slide 18: VYN202: BD2 selective BET inhibitor

    VYN202: BD2 selective BET inhibitor

  19. Slide 19: VYNE's Drug Design Strategy

    VYNE’s Drug Design Strategy Optimize benefit/risk profile of BET inhibitors to target immune-mediated diseases Repibresib (VYN201) VYN202 Pan-BD BET Inhibitor BD2-Selective BET Inhibitor Maximize local effect & Improve efficacy and tolerability minimize systemic exposure through BD2-selectivity • Ti

  20. Slide 20: VYN202: A Novel BD2-Selective BET Inhibitor for Immune-Mediated Diseases

    VYN202: A Novel BD2-Selective BET Inhibitor for Immune-Mediated Diseases • VYN202 is an innovative, oral BD2-selective BET inhibitor • VYN202 is believed to be the most potent and BD2-selective BET Inhibitor in clinical development1 which is designed to improve efficacy and tolerability • Phase 1 SA

  21. Slide 21: Maximizing On-target Potency vs. BD2 and Minimizing Affinity to BD1

    Maximizing On-target Potency vs. BD2 and Minimizing Affinity to BD1 May Be The Key to Optimizing the Benefit/Risk Profile of BET Inhibitors for Immune-Mediated Diseases VYN202 is believed to be the most potent and BD2-selective BET Inhibitor in clinical development1 which is designed to improve effi

  22. Slide 22: VYN202: Preclinical Efficacy Models

    VYN202: Preclinical Efficacy Models

  23. Slide 23: VYN202: Comparable to Deucravacitinib in Preclinical Psoriasis Model

    VYN202: Clinical and Biomarker Effects Comparable to Deucravacitinib in Preclinical in vivo Model of Psoriasis Day 15 After 7 days of treatment 150 IMI/Placebo IMI/VYN202 3mg/kg IMI/Deucravacitinib 3mg/kg % Change in PASI Score 125 100 VYN202 and Deucravacitinib 75 surpassed PASI-90 by day 7 of trea

  24. Slide 24: VYN202: Anti-Arthritic Effect in Preclinical Models of Arthritis

    VYN202: Anti-Arthritic Effect and Decreased Antibody Levels Demonstrated in Preclinical Models of Arthritis Collagen-Induced Arthritis Model Adjuvant-Induced Arthritis Model • VYN202’s increased potency and selectivity led to improved outcomes • Comparable effect on paw volume and IgG1 expression to

  25. Slide 25: VYN202 Results Show Strong Correlation with VYN201 Results

    VYN202 Results Show Strong Correlation with VYN201 Results Reinforcing BET potential and role of BD2 inhibition in treatment of I&I diseases Psoriasis Model Psoriasis Model Arthritis Model (CIA) 16 VYN202 Sham Control VYN201 VYN202 Deucra 14 100 Locally-administered 71% CIA+Placebo 12 CIA+Dexamethas

  26. Slide 26: VYN202: Phase 1a SAD/MAD Data

    VYN202: Phase 1a SAD/MAD Data

  27. Slide 27: VYN202 Phase 1a SAD/MAD Trial Design and Key Objectives

    VYN202 Phase 1a SAD/MAD Trial Design and Key Objectives First-in-human trial in healthy volunteers complete Healthy Volunteers SAD MAD Placebo-controlled study evaluating safety, tolerability, PK and PD Key Objectives Trial size: N=40 Trial size: N=32 Assess: Evaluated 4 doses of VYN202 Evaluated 3

  28. Slide 28: VYN202 Demonstrated a Favorable Safety and Tolerability Profile in Phase 1

    VYN202 Demonstrated a Favorable Safety and Tolerability Profile in Phase 1 VYN202 was generally well tolerated in Phase 1 MAD with no drug related AEs of special interest historically associated with BET inhibitor class MAD Results Treatment Emergent AEs Placebo VYN202 Number of Subjects Reporting (

  29. Slide 29: VYN202 Phase 1a MAD Results: Selected Laboratory Data

    VYN202 Phase 1 MAD Results: Selected Laboratory Data All laboratory results within normal limits throughout treatment and follow-up period Platelets Neutrophils Lymphocytes 7.0 5.0 400 6.0 4.0 Mean 10^3/uL (±SE) Mean 10^3/uL (±SE) Mean 10^3/uL (±SE) 5.0 300 4.0 3.0 200 3.0 2.0 Grade 1 (<150-75) 2.0

  30. Slide 30: VYN202 Phase 1a SAD and Day 14 MAD Pharmacokinetics

    VYN202 Phase 1 SAD and Day 14 MAD Pharmacokinetics Single Ascending Dose PK Multiple Ascending Dose PK, Day 14 4.5 4.5 4.0 IC90 4.0 IC90 Mean (±SEM) Concentration (ng/mL) Mean (±SEM) Concentration (ng/mL) 3.5 4.0mg QD 3.5 1mg QD 2.0mg QD 0.5mg QD 3.0 3.0 1mg QD 0.5mg QOD 2.5 0.5mg QD 2.5 2.0 2.0 1.5

  31. Slide 31: Pharmacokinetics Showed Strong Correlation with Target Engagement

    Pharmacokinetics Showed Strong Correlation with Target Engagement Dose-dependent induction of HEXIM-1 with maximum effect observed at 0.5-1 mg QD Multiple Ascending Dose PK, Day 14 Multiple Ascending Dose HEXIM-1 Induction, Day 14 4.5 1.6 0.5mg QOD Mean (±SEM) Fold Induction vs. Predose 4.0 IC90 1.5

  32. Slide 32: Demonstrated Impact on Pro-Inflammatory and Disease Related Cytokines

    Demonstrated Impact on Pro-Inflammatory and Disease Related Cytokines Ex Vivo Inhibition of Disease Related Cytokines1, Day 14 40% Mean % Change from Baseline 30% 20% 10% Significant inhibition of key cytokines 0% relevant to several immune-mediated diseases -10% -20% -30% -40% Comparable inhibitory

  33. Slide 33: Majority of Cytokine Suppression Occurred in Concentrations at 1 mg or Below

    Majority of Cytokine Suppression Occurred in Concentrations at 1 mg or Below in preclinical in vitro tests at fixed concentrations of VYN202 ranging from 0 to 10 ng/mL 0 VYN202 exhibited steep exposure/response curves, consistent -25 with preclinical disease models % Inhibition -50 Majority of inhib

  34. Slide 34: VYN202 Phase 1a MAD Data Summary

    VYN202 Phase 1a MAD Data Summary Safety Pharmacokinetics Pharmacodynamics • Demonstrated favorable safety and • Favorable PK profile • Robust pharmacodynamic activity on target tolerability profile engagement and inflammatory biomarkers • Data supports once-daily dosing regimen in ex vivo assays • N

  35. Slide 35: VYN202 Enhanced Phase 1b Study Design in Moderate-to-Severe Plaque Psoriasis

    VYN202 Enhanced Phase 1b Study Design in Moderate-to-Severe Plaque Psoriasis Top-line results from 12-week placebo-controlled treatment period expected YE 2025 N = up to 80 subjects with moderate-to-severe plaque psoriasis Screening period Placebo-controlled treatment period Safety follow-up (30 day

  36. Slide 36: Multiple Paths to Potential Value Creation Across BET Inhibitor Programs

    Multiple Paths to Potential Value Creation Across BET Inhibitor Programs 2024 2025 2026 Q4 Q1 Mid-Year YE Q1 LPI Top-line VYN201 P2b Trial in Results P2b P2b Extension Vitiligo Trial in Readout Vitiligo P1a MAD P1b Trial in Top-line VYN202 Results PsO Results P1b Initiated PsO Cash Runway into 2H 20

  37. Slide 37: NASDAQ: VYNE

    ld A THeRAPEuTics NASDAQ: VYNE

  38. Slide 38: Appendix

    Appendix %VYNE’

  39. Slide 39: Pathogenesis of Vitiligo is Primarily Linked to CD8+ T-Cell Proliferation and Hyperactivity

    Pathogenesis of Vitiligo is Primarily Linked to CD8+ T-Cell Proliferation and Hyperactivity Repibresib (VYN201) has demonstrated marked inhibition of CD8+ t-cell expansion and activity at levels favorable to ruxolitinib CD8+ T-cell Proliferation CD8+ T-cell Activation Marker IFNγ CD8+ T-cell Viabili

  40. Slide 40: Repibresib (VYN201) P1b Baseline Demographic and Clinical Characteristics

    Repibresib (VYN201) P1b Baseline Demographic and Clinical Characteristics 0.5% Cohort 1% Cohort 2% Cohort Total (N=10) (N=10) (N=9) (N=29) Age - year mean 49.2 53.2 57.0 52.9 Age group - no. / % 0 0% 0 0% 0 0% 0 0% 12-17 0 0% 0 0% 0 0% 0 0% 18-64 9 90% 8 80% 8 89% 25 86% >=65 1 10% 2 20% 1 11% 4 14%

  41. Slide 41: Demonstrated Favorable Safety & Tolerability Profile in P1b

    Demonstrated Favorable Safety & Tolerability Profile in P1b Adverse Events Local Skin Tolerability Mean Score No serious adverse events reported Assessment Range 0 (None) to 3 (Severe) Burning/Stinging 0.26 No treatment related discontinuations Scaling 0.15 Dryness 0.22 All TEAEs classified as mild

VYNE Therapeutics — Investor Presentation (March 2025) on 6ix